Fast on GlaxoSmithKline's heels, Aurinia wins OK to steer a second lupus nephritis drug straight to the market
GlaxoSmithKline’s Benlysta isn’t alone in the small circle of approved lupus nephritis drugs anymore.
Little Aurinia Pharmaceuticals has gotten the green light from the FDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.